AFM-11
- Generic Name
- AFM-11
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT02848911
- Locations
- 🇵🇱
Independent Public Healthcare Municipal Hospital, Chorzow, Poland
🇷🇺Almazov NW Federal Medical Research Center, St. Petersburg, Russian Federation
🇷🇺First Pavlov State Medical University, St. Petersburg, Russian Federation
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
Phase 1
Terminated
- Conditions
- Relapsed B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT02106091
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇵🇱SP ZOZ University Hospital Krakow, Krakow, Poland
🇵🇱MTZ Clinical Research, Warsaw, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath